Aqueous Humor Biomarker Profiling for Early Vitreoretinal Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The molecular physiology of aqueous humor in the eye is poorly understood due to its small sample volume, low protein concentration, and sparse cellular components, limiting effective methods for monitoring molecular pathophysiology and human health.
Innovation Solution
Identifying and measuring specific biomarkers such as stromelysin-2 (MMP10), neuropilin-1 (NRP1), semaphorin 3C (SEMA3C), hes family bHLH transcription factor 5 (HES5), and fibroblast growth factor receptor like 1 (FGFRL1) in aqueous humor samples, using assays like aptamer-based proteomic analysis, to predict biological age and age-related pathologies, and monitoring diseases like AMD, diabetic retinopathy, and other vitreoretinal conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If aqueous humor is used for molecular analysis, then early detection of age-related diseases is enabled, but the small sample volume and low protein concentration limit effective monitoring
Solution Approach 1:
The patent applies parameter changes by switching from traditional bulk analysis methods to targeted proteomic approaches that measure specific biomarkers at ultra-low concentrations. This involves changing the detection parameters to achieve femtomolar to attomolar sensitivity, enabling accurate measurement despite limited sample volume and low protein concentration in aqueous humor.
Solution Approach 2:
The patent extracts and measures specific biomarkers of interest from the complex aqueous humor matrix. By focusing on particular proteins and peptides that indicate age-related pathology, the method overcomes the limitation of low overall protein concentration by concentrating analytical effort on detecting specific molecular signatures at trace levels.
2Loss of information
If comprehensive proteomic profiling is performed on aqueous humor, then molecular pathophysiology can be monitored, but the sparse cellular components and low protein concentration make exploration difficult
Solution Approach 1:
The patent transforms the analytical approach by changing from quantitative bulk proteomics to qualitative and semi-quantitative targeted proteomics. This parameter change enables comprehensive molecular profiling by detecting specific proteins at very low concentrations, recovering information that would be lost in traditional methods requiring higher protein abundance.
Solution Approach 2:
The patent replaces traditional mechanical separation and concentration methods with highly sensitive mass spectrometry-based detection systems. This substitution allows direct detection of low-abundance proteins in aqueous humor without requiring physical concentration steps, preserving the native molecular composition information.
3Loss of time
If biomarker levels are measured to predict biological age, then early intervention is enabled, but accurate measurement requires sophisticated analytical methods
Solution Approach 1:
The patent segments the complex analytical task into targeted measurement of specific biomarker panels. By dividing the proteomic analysis into focused assays for age-related biomarkers, the method achieves rapid results suitable for clinical timing while managing analytical complexity through modular, targeted approaches rather than comprehensive untargeted analysis.
Data Source
AI summary
Compositions, methods, and kits are provided for diagnosing vitreoretinal diseases and age-related pathologies. In particular, aqueous humor biomarkers have been identified that correlate with biological aging and age-related pathologies and morbidity. The use of such biomarkers may allow earlier intervention in treatment of aging-related diseases. In addition, methods of using aqueous humor biomarkers for prognosis, diagnosis, and monitoring treatment of vitreoretinal diseases are also provided.